Effects of erythropoietin (epoetin-alfa) on infarct size and left ventricular remodeling in survivors of large myocardial infarctions

Trial Profile

Effects of erythropoietin (epoetin-alfa) on infarct size and left ventricular remodeling in survivors of large myocardial infarctions

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms REVEAL
  • Most Recent Events

    • 18 May 2012 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 18 May 2012 Actual initiation date changed from 1 Sep 2006 to 1 Sep 2005, lead trial investigator added (Lakatta EG) as reported by ClinicalTrials.gov.
    • 18 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top